First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Small Pharma, a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that the first patient has been dosed in the company’s Phase IIa clinical trial for its lead N,N-dimethyltryptamine (“DMT”) candidate, SPL026, which, in combination with psychotherapy, is intended to serve as a possible treatment of Major Depressive Disorder (“MDD”).